Ascendis Pharma A/S
Ascendis Pharma A/S (ASND) Stock Overview
Explore Ascendis Pharma A/S’s financial performance, market position, analyst ratings, and future outlook.
Analyst Recommendations
Price Targets
Company Profile
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Mr. Jan Moller Mikkelsen
1,017
Tuborg Boulevard 12, Hellerup
2015